This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

SafetyAdultAdults ChildrenChildrenIndications and DosingAdultAdults ChildrenChildrenDevicesPenPen PresentationGoQuickGoQuick PresentationMiniQuickMiniQuick PresentationSupportGroSupportEndocrine HelplineHomecareStock updatesHomecareResourcesMaterialsVideosEvents
Prescribing Information for Genotropin® (somatropin) can be found here. Adverse event reporting information can be found at the bottom of the page

Genotropin (somatropin) Pen

The Genotropin®️ Pen is reusable and offers flexible dosing in 5.3 mg and 12 mg presentations.

Genotropin® Pen1,2

Genotropin® Pen cartridges are available in two dosage presentations: 5.3 mg and 12 mg strengths. 

Patients requiring a dose of under 0.5 mg/day are advised to use the 5.3 mg pen. Patients requiring a higher dose are advised use the 12 mg pen. This is to ensure patients minimise wastage. 

Genotropin Pen 5.3mg Dosing

This table shows how many injection button clicks are necessary to administer Genotropin based on the prescribed dose for the patient. One injection button clicks represents a 0.1 mg dose increment.

Genotropin Pen 12mg Dosing

This table shows how many injection button clicks are necessary to administer Genotropin based on the prescribed dose for the patient. One injection button clicks represents a 0.2 mg dose increment.

Key Features1,2 

Please refer to the prescribing information for full information

Adjustable dosing
  • Two dosage formats: Genotropin® pen cartridges are available in two dosage presentations: 5.3mg and 12mg strengths.
  • Patients requiring a dose of under 0.5 mg/day should use the 5.3 mg pen. 
  • Patients requiring a higher dose should use the 12 mg pen.
Digital dose display

Ensures correct and accurate dosing.

Dial-back mechanism

Facilitates error correction and reduces waste.

Pen administration
  • Genotropin pen comes with an optional needle guard to hide the needle for patients who are anxious about needles.
  • Colour Coding: Cartridges are colour coded to facilitate confirmation that the correct dose of somatropin has been dispensed.
Storage
  • Genotropin pen comes in a hard, protective case, which can be used for everyday storage or transportation.
  • Once loaded, the Genotropin® pen should be stored in the refrigerator at 2-8°C, along with the cartridges. 
  • Cartridges must be kept in the refrigerator before reconstitution, not just once loaded into the pen.
Customisation
  • Each pen comes with two interchangeable side panels with matching lids to allow patients to select or change their pen colour.
  • Options for customisation of the Genotropin pen are available via the Endocrine Helpline.
How to use the Genotropin Pen

Watch National Endocrine Clinical Training Lead Claire Snow demonstrate how to use the Genotropin Pen.

Reference:1. GENOTROPIN Instructions for Use- 5.3mg Pen
2. GENOTROPIN Instructions for Use- 12mg Pen
PP-GEN-GBR-1688. March 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​​​​​​​​
 
You are now leaving PfizerPro 
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​